Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene

被引:21
|
作者
Lima, Francisco Pignataro [1 ,2 ,4 ,5 ]
Bousquet, Marina [1 ,2 ]
Gomez-Brouchet, Anne [3 ]
de Paiva, Geisilene Russano [3 ]
Amstalden, Eliane Maria Ingrid [5 ]
Soares, Fernando Augusto [6 ]
Dastugue, Nicole [1 ,2 ]
Vassallo, Jose [5 ]
Brousset, Pierre [1 ,2 ]
机构
[1] Ctr Physiopathol Toulouse Purpan, INSERM, Toulouse, France
[2] Univ Toulouse 3, Dept Pathol, F-31062 Toulouse, France
[3] Hop Rangueil, Dept Pathol, Toulouse, France
[4] Purpan Hosp, Cytogenet Lab, Toulouse, France
[5] Univ Estadual Campinas, Fac Med Sci, Dept Pathol, Campinas, Brazil
[6] Hosp Canc, Dept Pathol, Sao Paulo, Brazil
关键词
BCL2; c-MYC; fluorescence in situ hybridization; FISH; bone; B-cell lymphoma;
D O I
10.1309/CMPGPYTMFRM6RVQR
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We selected a series of 63 primary diffuse large B-cell lymphomas (DLBCLs) of bone collected in tissue microarrays from centers in France and Brazil. These cases were classified according to the expression of antigens associated with germinal center (GC; n = 42) or non-GC (n = 21) stages of B-cell differentiation. By fluorescence in situ hybridization, we found a substantial number of cases with a rearrangement of BCL2 (9132) and c-MYC (n = 3), whereas the PAX5, BCL6, BCL1/cyclin D1, and ALK genes were in germline configuration. It is interesting that I case, with a GC phenotype, showed dual B CL2 and c-MYC rearrangement. The majority of the cases with rearrangements were of the GC phenotype. These results, associated with the lack of BCL6 rearrangement, suggest that bone DLBCL represents a specific group within extranodal B-cell lymphomas.
引用
收藏
页码:723 / 726
页数:4
相关论文
共 50 条
  • [31] The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma
    Patrascu, Ana-Maria
    Rotaru, Ionela
    Olar, Lavinia
    Patrascu, Stefan
    Ghilusi, Mirela-Corina
    Neamtu, Simona-Daniela
    Nacea, Janina Georgiana
    Gluhovschi, Adrian
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (03) : 837 - 843
  • [32] MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
    Perry, Anamarija M.
    Alvarado-Bernal, Yuridia
    Laurini, Javier A.
    Smith, Lynette M.
    Slack, Graham W.
    Tan, King L.
    Sehn, Laurie H.
    Fu, Kai
    Aoun, Patricia
    Greiner, Timothy C.
    Chan, Wing C.
    Bierman, Philip J.
    Bociek, Robert G.
    Armitage, James O.
    Vose, Julie M.
    Gascoyne, Randy D.
    Weisenburger, Dennis D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (03) : 382 - 391
  • [33] MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma
    Lu, Ting-Xun
    Fan, Lei
    Wang, Li
    Wu, Jia-Zhu
    Miao, Kou-Rong
    Liang, Jin-Hua
    Gong, Qi-Xing
    Wang, Zhen
    Young, Ken H.
    Xu, Wei
    Zhang, Zhi-Hong
    Li, Jian-Yong
    ONCOTARGET, 2015, 6 (21) : 18374 - 18388
  • [34] Bcl-6 and c-Myc are rarely co-expressed in adult diffuse large B-cell lymphoma
    Wagner, Simon D.
    Amen, Furrat
    Trivedi, Pritesh S.
    Horncastle, Donna
    Elderfield, Kay
    Naresh, Kikkeri N.
    LEUKEMIA & LYMPHOMA, 2007, 48 (08) : 1510 - 1513
  • [35] Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma
    Bing Xia
    Le Zhang
    Shan-Qi Guo
    Xiao-Wu Li
    Fu-Lian Qu
    Hai-Feng Zhao
    Lian-Yu Zhang
    Bao-Cun Sun
    James You
    Yi-Zhuo Zhang
    World Journal of Gastroenterology, 2015, (08) : 2433 - 2442
  • [36] Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma
    Xia, Bing
    Zhang, Le
    Guo, Shan-Qi
    Li, Xiao-Wu
    Qu, Fu-Lian
    Zhao, Hai-Feng
    Zhang, Lian-Yu
    Sun, Bao-Cun
    You, James
    Zhang, Yi-Zhuo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (08) : 2433 - 2442
  • [37] Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
    Akyurek, Nalan
    Uner, Aysegul
    Benekli, Mustafa
    Barista, Ibrahim
    CANCER, 2012, 118 (17) : 4173 - 4183
  • [38] Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
    Ye, Qing
    Xu-Monette, Zijun Y.
    Tzankov, Alexandar
    Deng, Lijuan
    Wang, Xiaoxiao
    Manyam, Ganiraju C.
    Visco, Carlo
    Montes-Moreno, Santiago
    Zhang, Li
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Zu, Youli
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    van Krieken, J. Han
    Huh, Jooryung
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Parsons, Ben M.
    Moller, Michael B.
    Piris, Miguel A.
    Winter, Jane N.
    Medeiros, L. Jeffrey
    Hu, Shimin
    Young, Ken H.
    ONCOTARGET, 2016, 7 (03) : 2401 - 2416
  • [39] CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma
    Gong, Qi-Xing
    Wang, Zhen
    Liu, Chong
    Li, Xiao
    Lu, Ting-Xun
    Liang, Jin-Hua
    Xu, Wei
    Li, Jian-Yong
    Zhang, Zhi-Hong
    JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (09) : 795 - 801
  • [40] B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
    Snuderl, Matija
    Kolman, Olga K.
    Chen, Yi-Bin
    Hsu, Jessie J.
    Ackerman, Adam M.
    Dal Cin, Paola
    Ferry, Judith A.
    Harris, Nancy Lee
    Hasserjian, Robert P.
    Zukerberg, Lawrence R.
    Abramson, Jeremy S.
    Hochberg, Ephraim P.
    Lee, Hang
    Lee, Alfred I.
    Toomey, Christiana E.
    Sohani, Aliyah R.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (03) : 327 - 340